Project Grant HT94252510525

The National Cancer Institute (NCI), through the Cancer Treatment Research Federal Grant Program (CFDA 93.395), awarded a $219,351 Project Grant (R21CA296696) to The Institute for Cancer Research (ICR) to assess the efficacy and toxicity of T3 (the active form of thyroid hormone) for the treatment of medulloblastoma, the most common malignant brain tumor in children. The research aims to evaluate the toxicity, pharmacokinetics, and pharmacodynamics of T3 in tumor-bearing mice, as well as examine...

This National Cancer Institute project grant of $808,336 provides funding from September 2022 through August 2025 to investigate the effects of androgen receptor antagonism on human T cell function. The University of Portland will determine how androgen deprivation therapies used in prostate cancer treatment impact the adaptive immune response. Researchers will study the impact of the clinically relevant androgen receptor antagonist enzalutamide on T cells isolated from healthy volunteers in...

The Project Grant award R01CA287491, totaling $720,416, was provided by the National Cancer Institute (NCI) under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394). The award aims to develop a novel "theranostic" (therapeutic and diagnostic) approach using chimeric antigen receptor (CAR) T-cell therapy for the treatment of neuroendocrine prostate cancer (NEPC). The key products and services to be delivered include: Evaluating the therapeutic efficacy of...

This $559,587 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Institute For Cancer Research (ICR) supports research aimed at understanding how thyroid hormone can induce differentiation and inhibit the growth of medulloblastoma, the most common malignant brain tumor in children. The grant will fund three specific aims: 1) examining how thyroid hormone promotes medulloblastoma cell differentiation, 2) investigating how tumor cell...

This federal Project Grant award of $644,622 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to enhance radioligand therapy for prostate cancer through the development of biomarker and dosimetry-guided personalized treatment approaches. The key objectives are to: 1) develop a novel method for bone marrow dosimetry using macro/micro Monte Carlo modeling, 2) build predictive models to estimate absorbed radiation doses from pre-therapy PET...

This Federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) program, provides $245,472.00 to Duke University to conduct research on manipulating sex hormone signaling for therapeutic benefit in liver cancer. The key objectives are to: 1) Measure the effect of androgen receptor (AR) signaling on the oncogenic traits of hepatocellular carcinoma (HCC) models, 2) Define the transcriptional profile of AR in HCC, and 3) Determine the...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $440,333 to Brigham Young University to develop a novel chimeric autoantigen receptor (CAAR) T cell therapy for the treatment of Graves' disease, an autoimmune condition that causes hyperthyroidism. The goal is to generate CAAR T cells that can eliminate the autoreactive B cells producing antibodies that stimulate the thyroid, potentially...

This federal Project Grant award of $672,000.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports a research project at the Albert Einstein College of Medicine titled "A NOVEL SYNTHETIC LETHAL VULNERABILITY UNCOVERED BY INHIBITING ONE-CARBON METABOLISM IN ANAPLASTIC THYROID CANCER". The project aims to investigate a novel therapeutic approach for anaplastic thyroid cancer, an aggressive form of the disease, by targeting...

The National Cancer Institute (NCI) awarded a $1,948,592 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Washington University to conduct a Phase 1 clinical trial assessing the safety, tolerability, pharmacokinetics, and anti-tumor activity of the novel ACK1 inhibitor (R)-9B in patients with castration-resistant prostate cancer (CRPC). The grant period runs from August 15, 2024 to July 31, 2029. The study aims to evaluate (R)-9B's ability to overcome CRPC resistance...

This Project Grant award, totaling $482,236 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research to develop a new targeted therapy for patients with HER2-low metastatic colorectal cancer (mCRC). The principal investigator at the Sloan-Kettering Institute for Cancer Research will conduct a Phase 2 clinical trial to evaluate the safety and efficacy of combining the antibody-drug conjugate trastuzumab deruxtecan (T-DXD) with the...